Sox4 is a master regulator of epithelial-mesenchymal transition by controlling ezh2 expression and epigenetic reprogramming by Tiwari, Neha et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Sox4 is a master regulator of epithelial-mesenchymal transition by
controlling ezh2 expression and epigenetic reprogramming
Tiwari, Neha; Tiwari, Vijay K; Waldmeier, Lorenz; Balwierz, Piotr J; Arnold, Phil; Pachkov, Mikhail;
Meyer-Schaller, Nathalie; Schübeler, Dirk; van Nimwegen, Erik; Christofori, Gerhard
Abstract: Gene expression profiling has uncovered the transcription factor Sox4 with upregulated ac-
tivity during TGF-￿-induced epithelial-mesenchymal transition (EMT) in normal and cancerous breast
epithelial cells. Sox4 is indispensable for EMT and cell survival in vitro and for primary tumor growth
and metastasis in vivo. Among several EMT-relevant genes, Sox4 directly regulates the expression of
Ezh2, encoding the Polycomb group histone methyltransferase that trimethylates histone 3 lysine 27
(H3K27me3) for gene repression. Ablation of Ezh2 expression prevents EMT, whereas forced expression
of Ezh2 restores EMT in Sox4-deficient cells. Ezh2-mediated H3K27me3 marks associate with key EMT
genes, representing an epigenetic EMT signature that predicts patient survival. Our results identify Sox4
as a master regulator of EMT by governing the expression of the epigenetic modifier Ezh2.
DOI: 10.1016/j.ccr.2013.04.020
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-79475
Originally published at:
Tiwari, Neha; Tiwari, Vijay K; Waldmeier, Lorenz; Balwierz, Piotr J; Arnold, Phil; Pachkov, Mikhail;
Meyer-Schaller, Nathalie; Schübeler, Dirk; van Nimwegen, Erik; Christofori, Gerhard (2013). Sox4 is
a master regulator of epithelial-mesenchymal transition by controlling ezh2 expression and epigenetic
reprogramming. Cancer Cell, 23(6):768-83. DOI: 10.1016/j.ccr.2013.04.020
Tiwari et al. 
1 
	  
Sox4 is a master regulator of epithelial-mesenchymal transition  
by controlling Ezh2 expression and epigenetic reprogramming 
 
Neha Tiwari1,4, Vijay K. Tiwari2,5, Lorenz Waldmeier1, Piotr J. Balwierz3, Phil Arnold3, Mikhail 
Pachkov3, Nathalie Meyer-Schaller1, Dirk Schübeler2, Erik van Nimwegen3, and Gerhard 
Christofori1* 
 
1Department of Biomedicine, University of Basel, Basel, Switzerland 
2Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland 
3Biozentrum, University of Basel, and Swiss Institute of Bioinformatics, Basel, Switzerland 
4Current address: Institute of Physiological Chemistry, University Medical Center, Johannes 
Gutenberg University Mainz, Mainz 
5Current address: Institute for Molecular Biology gGmbH (IMB), Mainz, Germany 
 
*Corresponding author:   Gerhard Christofori 
Department of Biomedicine 
University of Basel 
Mattenstrasse 28 
4058 Basel 
Switzerland 
Tel. +41 61 267 35 64 
Fax. +41 61 267 35 66 
 
e-mail: Gerhard.christofori@unibas.ch 
 
 
Running title: Sox4 regulates EMT via Ezh2 
 
Subject Category: Molecular biology of disease, cancer 
 
Keywords: Sox4, TGFβ, EMT, Ezh2, tumorigenesis, metastasis 
 
 
 
 
 
Word Count: 63’993 characters including spaces (all text, references, figure legends) 
8 Figures, Supplemental Information including 6 Supplemental Figures, 2 Supplemental Tables, 
Supplemental Figure Legends, and Supplemental Experimental Procedures. 
  
Tiwari et al. 
2 
	  
 
Summary  
Gene expression profiling has uncovered the transcription factor Sox4 with up-regulated activity 
during TGFβ-induced EMT in normal and cancerous breast epithelial cells. Sox4 is 
indispensable for EMT and cell survival in vitro and for primary tumor growth and metastasis in 
vivo. Among several EMT-relevant genes, Sox4 directly regulates the expression of Ezh2, 
encoding the Polycomb group histone methyltransferase that trimethylates histone 3 lysine 27 
(H3K27me3) for gene repression. Ablation of Ezh2 expression prevents EMT, while forced 
expression of Ezh2 restores EMT in Sox4-deficient cells. Ezh2-mediated H3K27me3 marks 
associate with key EMT genes, representing an epigenetic EMT signature that predicts patient 
survival. Our results identify Sox4 as a master regulator of EMT by governing the expression of 
the epigenetic modifier Ezh2. 
 
Significance 
An epithelial-mesenchymal transition (EMT) is a key process during organismal development 
and the progression of epithelial tumors to metastatic cancers. Here, we identify the 
transcription factor Sox4 as a master regulator of EMT. Sox4 appears to act highly upstream in 
the epistatic hierarchy of EMT regulation. It controls a number of EMT-relevant genes as well as 
Ezh2. Conversely, Ezh2 is able to functionally replace Sox4 during EMT and regulates the 
expression of a number of EMT-associated genes. Ezh2 thus represents one critical Sox4 target 
gene during EMT. The results exemplify an important interplay between transcriptional and 
epigenetic control during EMT and suggest that the inhibition of Ezh2 could be an attractive 
avenue for the therapeutic intervention of malignant tumor progression. 
 
Highlights 
• Sox4 is critical for EMT and for experimental primary tumor growth and metastasis 
• Sox4 directly regulates EMT-relevant genes, among them Ezh2 
• Ezh2 function and thus H3K27me3 are required for EMT 
• The expression of Ezh2-regulated genes is predictive for patient survival  
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Introduction 
Epithelial–mesenchymal transition (EMT) is a cellular mechanism known to constitute the core 
of normal embryonic development (Hanahan and Weinberg, 2011; Kalluri, 2009; Kalluri and 
Weinberg, 2009; Nieto, 2010; Polyak and Weinberg, 2009; Thiery and Sleeman, 2006). Similar, 
yet pathophysiological transitions occur during the progression of epithelial tumors, endowing 
cancer cells with increased motility and invasiveness to seed metastasis and, sometimes, after 
metastatic dissemination to re-differentiate into epithelial structures by mesenchymal-epithelial 
transition (Kang and Massague, 2004; Thiery and Morgan, 2004). Multiple oncogenic events 
and signaling pathways, mediated for example by transforming growth factor β (TGFβ), 
hepatocyte growth factor (HGF), Wnt and Notch signaling or by oncogenic Src or Ras activation, 
are implicated in the induction of EMT (Hanahan and Weinberg, 2011; Kalluri, 2009; Kalluri and 
Weinberg, 2009; Nieto, 2010; Polyak and Weinberg, 2009; Thiery and Sleeman, 2006). 
Sox4 is a member of the Sox (SRY-related HMG-box) family of transcription factors with 
a critical role in embryonic development and in cell-fate determination during organogenesis of 
the heart (Restivo et al., 2006; Schilham et al., 1996), pancreas (Lioubinski et al., 2003; Wilson 
et al., 2005) and brain (Cheung et al., 2000; Hong and Saint-Jeannet, 2005), and in B and T 
lymphocyte differentiation (Cheung et al., 2000; Hong and Saint-Jeannet, 2005; Lioubinski et al., 
2003; Schilham et al., 1997; Schilham et al., 1996; van de Wetering et al., 1993; Wilson et al., 
2005). Sox4 gene expression is up-regulated in many cancer types, and increased Sox4 activity 
contributes to cellular transformation (Liu et al., 2006; Shin et al., 2004), cell survival (Aaboe et 
al., 2006; Ahn et al., 2002; Liu et al., 2006; Pramoonjago et al., 2006) and metastasis (Liao et 
al., 2008; Tavazoie et al., 2008). For example, restoration of miR-335 expression suppresses 
lung and bone metastasis in human cancer cells by interfering with the expression of Sox4 
(Tavazoie et al., 2008). Interestingly, Sox4 also directly modulates key cellular regulators, 
including the genes encoding for epidermal growth factor receptor (EGFR), tenascin-C, heat 
shock protein 70 (Hsp70), frizzled homolog 5 (Fzd5), Delta-like 1 (Dll1), Patched-1 (Ptch1), the 
transcriptional regulators Mll, Foxa1, Znf281 and Nkx3-1, and components of the RNAi 
machinery, including Dicer, Argonaute 1 and RNA helicase A (Scharer et al., 2009). Finally, 
Sox4 regulates Wnt signaling by directly binding to β-catenin and Tcf family members (Sinner et 
al., 2007). Most recently, Sox4 has been reported to induce EMT and to cooperate with 
oncogenic Ras in breast cancer progression (Zhang et al., 2012), however, its direct 
transcriptional target genes during EMT have remained elusive. Here, we demonstrate a central 
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role of Sox4 in EMT as well as in primary tumor growth and metastasis by directly regulating the 
expression of a number of genes with critical functions in EMT, including Ezh2. 
The histone methyltransferase Ezh2 (Enhancer of Zeste homolog 2) is a component of 
the Polycomb (PcG) repressive complex 2 (PRC2) which epigenetically regulates genes 
involved in cell fate decisions. Ezh2 specifically trimethylates nucleosomal histone H3 at lysine 
27 (H3K27me3), an epigenetic modification associated with gene silencing (Sparmann and van 
Lohuizen, 2006). A conditional knockout of the Ezh2 gene in basal keratinocytes leads a 
precocious acquisition of an epidermal barrier function in the embryo (Ezhkova et al., 2009), 
while a conditional knockout of Ezh2 in B-lymphocytes results in improper IgH re-arrangements 
(Su et al., 2003), suggesting a role for Ezh2 methyltransferase in cell differentiation and 
maturation. Ezh2 is found highly expressed in a variety of cancer types where the genomic loss 
of miR-101 leads to increased expression of Ezh2 and concomitant deregulation of epigenetic 
pathways, altogether resulting in cancer progression (Varambally et al., 2008). Furthermore, 
Ezh2 can induce EMT and increase the metastatic potential of prostate cancer cells by down-
regulation of DAB2IP, a tumor-suppressive Ras GTPase activating protein (RasGAP) (Chen et 
al., 2005; Min et al., 2010). Finally, low Ezh2 expression levels correlate with metastasis-free 
survival in breast cancer (Cao et al., 2008; Kleer et al., 2003). However, whether and how Ezh2-
mediated epigenetic mechanisms contribute to the transcriptional reprogramming that 
accompanies EMT is still poorly understood. 
 
Results 
Sox4 is required for EMT 
To identify critical genes underlying early, intermediate and late stages of EMT, we induced 
EMT in the untransformed normal murine mammary gland cell line NMuMG by treatment with 
TGFβ for 0, 1, 4, 7, 10 and 20 days (data not shown). During this time course, the cells 
underwent progressive EMT and acquired a complete mesenchymal morphology (Lehembre et 
al., 2008). Motif Activity Response Analysis [MARA; Suzuki et al., 2009)] of gene expression 
data derived from the EMT time course predicted several transcription factor binding motifs to 
be important regulators of the EMT expression dynamics, including a motif bound by Sox 
transcription factors (Figure S1A). Gene expression profiling and quantitative RT-PCR 
experiments revealed that Sox4 and 9 were the only Sox family members significantly up-
regulated in their expression during TGFβ-induced EMT in NMuMG cells (Figure S1B-D). Sox4 
expression was also robustly induced during EMT in a number of other cellular EMT systems, 
including TGFβ-induced EMT in Py2T murine breast cancer cells derived from a tumor of 
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MMTV-PyMT transgenic mice (Waldmeier et al., 2012), in MCF10A human breast  epithelial 
cells, in EpRas murine mammary epithelial cells (Figure S1D-G), and in HMEC human 
mammary epithelial cells (Kloeker et al., 2004). Sox4 expression was also increased in MCF7 
human breast cancer cells that exert full EMT upon shRNA-mediated knockdown of E-cadherin 
expression (Lehembre et al., 2008; Figure S1H).  
To directly assess the role of Sox4 and Sox9 in EMT, NMuMG cells were transfected 
with a pool of two different siRNAs against Sox4 (siSox4) and Sox9 (siSox9), as well as siSox4 
and siSox9 together, to transiently ablate the expression of Sox4 and Sox9 in the absence and 
presence of TGFβ, resulting in an efficient repression of Sox4 and Sox9 expression (Figure 1A; 
Figure S1I, J). As reported recently (Zhang et al., 2012), Sox4-ablated NMuMG cells were not 
able to undergo EMT and largely retained their epithelial morphology during TGFβ treatment, 
while cells transfected with control-siRNA (siControl) changed to a mesenchymal, fibroblastoid 
phenotype (Figure 1B). In contrast, the single ablation of Sox9 did not have any effect on TGFβ-
induced EMT, while the concomitant ablation of Sox4 and Sox9 mimicked the single ablation of 
Sox4 (Figure S1K, L). Immunofluorescence staining revealed that Sox4 depletion in the 
absence of TGFβ did not substantially affect the epithelial morphology of NMuMG cells (Figure 
1C). In the presence of TGFβ, Sox4-depleted cells maintained the epithelial markers E-cadherin 
and ZO-1 at the cell membrane, and the expression of the mesenchymal marker N-cadherin 
was decreased as compared to TGFβ-treated siControl cells (Figure 1C). Moreover, TGFβ-
mediated remodeling of the cytoskeleton from cortical actin to stress fibers, as determined by 
phalloidin staining, and focal adhesion formation, as determined by paxillin staining, were 
significantly reduced in siSox4 cells (Figure 1C, Figure S1M). The failure to lose epithelial and to 
gain mesenchymal marker expression in TGFβ-treated, Sox4-depleted cells was further 
confirmed by immunoblotting analysis (Figure 1D). Notably, Sox4 depletion in NMuMG cells 
treated previously with TGFβ for 15 days reverted these mesenchymal cells to an epithelial 
phenotype (Figure 1E). Similar to NMuMG cells, shRNA-mediated stable knockdown of Sox4 in 
Py2T cells markedly delayed TGFβ-induced EMT (Figure S1N-P). Together, these results 
demonstrate that Sox4 but not Sox9 is required for the induction and maintenance of TGFβ-
induced EMT in murine mammary epithelial cells. 
 
Sox4 is required and sufficient for cell survival and cell migration  
Sox4 has been implicated in cell survival in a variety of cancers (Hur et al., 2010; Pramoonjago 
et al., 2006; Shen et al., 2010). Indeed, Sox4-depleted NMuMG and Py2T cells also showed a 
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significant reduction in cell growth in comparison to control cells and displayed a discernable 
sensitivity towards TGFβ-mediated growth inhibition (Figure 2A, B). Propidium iodide staining 
followed by flow cytometry-based cell cycle analysis revealed a G0/G1 cell cycle arrest after 
Sox4 depletion (Figure 2C, D). Annexin-V staining demonstrated a marked increase in the 
levels of apoptosis in siSox4-transfected NMuMG cells (Figure 2E), but not in Py2T cells (data 
not shown). These results indicate that Sox4 is required for cell survival and proliferation during 
TGFβ-induced EMT and that the pro-survival function of Sox4 only becomes critical in non-
transformed cells. Cell migration is a characteristic feature of EMT and metastasis (Brabletz et 
al., 2005; Christofori, 2006; Grunert et al., 2003; Huber et al., 2005; Thiery and Sleeman, 2006). 
Transwell migration assays with the apoptosis-resistant Py2T breast cancer cells revealed that 
shSox4 Py2T cells migrated significantly less than shControl cells after long-term treatment with 
TGFβ (Figure 2F).  
We next asked whether Sox4 was sufficient to induce EMT. Transient expression of HA-
tagged Sox4 in NMuMG cells at the levels observed during TGFβ-induced EMT increased 
filopodia formation and cell scattering (Figure 3A) accompanied by the gain of the mesenchymal 
markers N-cadherin and fibronectin (Figure 3B, C). While its mRNA and protein levels were not 
apparently affected, E-cadherin was displaced at the cell junctions of HA-Sox4 expressing cells 
(Figure 3D). Stable expression of HA-tagged Sox4 in Py2T cells also induced mesenchymal cell 
morphology in the absence of TGFβ with a moderate loss of E-cadherin expression but a 
marked gain in N-cadherin and fibronectin expression (Figure 3E-G).  Furthermore, the forced 
expression of Sox4 promoted Py2T cell migration (Figure 3H). These results suggest that Sox4 
is not only required but also sufficient for the induction of an EMT.  
 
Sox4 is required for tumorigenesis and metastatic spread 
The critical role of Sox4 in EMT raised the question whether Sox4 contributes to malignant 
tumor progression and metastasis. First, computational analysis revealed a significant 
correlation between high Sox4 expression and poor metastasis-free survival in the “Schmidt” 
database of 200 early-stage, lymph node-negative breast cancer patients (Schmidt et al., 2008) 
(Figure 4A). The analysis of databases assembled of late-stage breast cancer patient data did 
not reveal a significant prognostic value for Sox4 expression (data not shown), suggesting that 
Sox4 may play a critical role in the early stages of the malignant progression of breast cancer.  
Next, we investigated the functional contribution of Sox4 to primary tumor growth and 
metastasis formation in vivo. Py2T cells stably expressing an shRNA against Sox4 (shSox4) 
and control-transfected cells (shControl), both expressing the firefly luciferase gene, were 
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orthotopically implanted into mammary fat pads of nude mice, and tumor growth and metastasis 
in lymph-nodes, lungs and livers were quantified. Quantitative RT-PCR (Figure S2A) and 
immunostaining of histological tumor sections (Figure 4B) documented an efficient depletion of 
Sox4 expression in the cultured cell line before implantation and in primary tumors, respectively. 
Ablation of Sox4 expression in Py2T cells lead to a significant reduction in primary tumor growth 
(Figure 4C). Luciferase activity levels representing the presence of tumor cells in distant organs 
were found decreased in axillary and inguinal lymph nodes and in lungs and livers of mice 
transplanted with shSox4 Py2T cells as compared to shControl Py2T cells (Figure S2B), even 
when the luciferase activities were normalized to the decreased primary tumor sizes observed 
with shSox4 Py2T cells (metastatic index; Figure 4D). The reduced ability of shSox4 Py2T cells 
to grow as primary tumors was also observed upon subcutaneous implantation into nude mice 
(Figure 4E).  
We next addressed whether Sox4 is required for metastasis formation in other cancer 
types. Similar to NMuMG cells, in B16-F10 melanoma cells Sox4 expression was increased 
upon TGFβ treatment (Figure S2C). Sox4 expression was then ablated in B16-F10 melanoma 
cells by stable expression of shRNA targeting Sox4 (shSox4; Figure S2D), and the cells were 
injected into the tail vein of C57Bl/6 mice. Quantification of lung metastasis showed that Sox4-
depleted B16-F10 cells were significantly impaired in lung colonization as compared to 
shControl-expressing B16-F10 cells (Figure S2E, F). Taken together, these results indicate that 
the transcription factor Sox4 exerts a critical function in primary tumor growth and metastasis 
formation. 
 
Ezh2 is a direct transcriptional target of Sox4  
The critical role of Sox4 in EMT and tumor progression motivated us to identify the genes that 
were directly regulated by Sox4. We first compared the genome-wide gene expression profiles 
of siControl and siSox4 NMuMG cells in the absence and presence of TGFβ. Genes found to be 
differentially expressed in dependence on Sox4 function were further analyzed for Sox4 binding 
motifs within one kilobase of their transcription start sites (Figure S1A). Of the 189 genes 
fulfilling these criteria (Table S1), 106 also changed in their expression levels during TGFβ-
induced EMT. Gene ontology analysis revealed that 32 of these genes have been previously 
implicated in processes relevant to tumor progression (Table S2). In order to identify the genes 
directly regulated by Sox4, we assessed the occupancy of Sox4 at the promoters of these 32 
genes. NMuMG cells transiently expressing a HA-tagged version of Sox4 (HA-Sox4) were 
subjected to Chromatin Immunoprecipitation (ChIP) with HA-specific antibodies followed by 
Tiwari et al. 
8 
	  
quantitative PCR using primers specific for the region spanning the Sox4 motif found in the 
promoter of these genes. Out of the 32 genes analyzed, the promoters of 16 and 12 genes were 
directly bound by Sox4 in NMuMG and Py2T cells respectively, including the key EMT genes 
Spred1, Edn1, Palld, Cyr61, Ereg, and Areg (Figure S3A - H and data not shown). Genes that 
were not immunoprecipitated by HA-antibody, as well as an intergenic region, served as 
negative controls (Figure S3I).   
Snail, Zeb and Twist family transcriptional repressors of E-cadherin gene expression are 
known to play critical roles in the induction of EMT. Hence, we assessed whether Sox4 is 
epistatic to the expression of these EMT inducers or whether they are regulating Sox4 
expression during EMT. Ablation of Sox4 expression in NMuMG cells resulted in the reduced 
expression of Snail2, Zeb2 and Twist1 but not Snail1 and Zeb1, while in Py2T cells the 
expression of all five repressors was reduced upon Sox4-depletion (Figure S3J-N and P-T). 
Conversely, when the five repressors were transiently expressed in NMuMG and Py2T cells, the 
levels of Sox4 mRNA were not affected (Figure S3O and U). Together, the data indicate that 
Sox4 acts upstream of the EMT inducers during EMT, most likely in an indirect manner, since 
none of the EMT inducers have been detected as a direct transcriptional target of Sox4.  
Interestingly, the Sox4-dependent gene expression profiling and ChIP experiments also 
revealed the promoter of the Ezh2 gene to be directly bound and regulated by Sox4 in NMuMG 
and Py2T cells (Figure 5A, B). Quantitative RT-PCR and immunoblotting showed that Sox4-
depletion lead to significantly reduced Ezh2 expression and a global reduction in H3K27me3 
levels in the presence of TGFβ in NMuMG and Py2T cells (Figure 5C). Moreover, the forced 
expression of Sox4 moderately increased Ezh2 mRNA and protein levels (Figure 3B, C, G). 
Finally, Ezh2 promoter activity was reduced upon Sox4 depletion in NMuMG cells in the 
presence of TGFβ, as determined by Ezh2 promoter-luciferase reporter assay (Figure 5D). 
These results indicate that Sox4 is required for Ezh2 expression during EMT. Yet, it should be 
noted that Ezh2 expression levels were already substantial in epithelial cells, where Sox4 
expression was low and did not markedly change with the increasing levels of Sox4 during 
TGFβ-induced EMT (Figure 5E, F; Figure 6B). Hence, Sox4 is required for the efficient 
expression of Ezh2 during TGFβ-induced EMT, but not in epithelial cells in the absence of 
TGFβ, suggesting that factors other than Sox4 are critical for Ezh2 gene expression in the 
epithelial state of the cells. Consistent with this notion, the dependence of Ezh2 expression on 
Sox4 became already apparent between 2 and 8 hours of TGFβ stimulation in NMuMG and 
Py2T cells (Figure 5E and F). 
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Loss of Ezh2 function impairs EMT and metastasis 
Based on the pleiotropic functions of Ezh2 in mediating the H3K27me3 repressive mark, we 
speculated whether a major aspect of EMT regulation by Sox4 was dependent on its regulation 
of Ezh2 gene expression. Indeed, similar to the ablation of Sox4, siRNA-mediated knockdown of 
Ezh2 (siEzh2) in NMuMG cells lead to an efficient downregulation of Ezh2 and retention of the 
epithelial phenotype of NMuMG cells upon TGFβ stimulation (Figure 6A, Figure S4A). 
Immunoblotting and immunofluorescence microscopy analysis demonstrated a failure to lose E-
cadherin and ZO-1 expression as well as a reduced gain in the expression of fibronectin and an 
impaired formation of actin stress fibers and focal adhesions in Ezh2-depleted cells as 
compared to siControl-treated cells (Figure 6B and C). These effects became even more 
apparent in NMuMG cells when both methyltransferases, Ezh1 and Ezh2, were concomitantly 
depleted (Figure 6A, C and Figure S4B-F). Similar to NMuMG cells, shRNA-mediated stable co-
depletion of Ezh1 and 2 in Py2T cells also delayed EMT (Figure S4G-I). Comparable to the 
ablation of Sox4 expression, Ezh2-depleted NMuMG cells showed significantly increased 
apoptosis, a block in G0/G1, and a substantial attenuation in their proliferation during TGFβ-
induced EMT (Figure 6D-F). Finally, similar to the depletion of Sox4 in B16-F10 melanoma cells, 
shRNA-mediated ablation of Ezh2 or Ezh1/2 together resulted in a significantly reduced ability 
of these cells to form lung metastasis upon intravenous injection (Figure S4J). Notably, the 
concomitant high expression of Ezh2 and Sox4 significantly correlated with poor metastasis-free 
survival of early-stage, lymph node-negative breast cancer patients (Schmidt et al., 2008) 
(Figure 6G).  
To directly assess whether Ezh2 is Sox4’s major transcriptional target required for its 
EMT-inducing function, we transiently ablated Sox4 in NMuMG and Py2T cells and 
concomitantly expressed Ezh2 by transient transfection of an Ezh2 expression plasmid. 
Notably, the forced expression of Ezh2 overcame the reduced expression of endogenous Ezh2 
upon Sox4 depletion and restored TGFβ-induced EMT and changes in marker expression that 
otherwise were repressed by Sox4 ablation in NMuMG and in Py2T cells (Figure 7A-C; Figure 
S5A, B). These results indicate that Ezh2 is one critical target of Sox4 transcriptional regulation 
during EMT and metastasis formation. 
 
Ezh2 regulates EMT genes via H3K27me3 modification of their promoters 
To identify the target genes that are modified by Ezh2-mediated H3K27me3 epigenetic imprint 
and that are regulated in their expression during EMT, we performed chromatin 
immunoprecipitation using a H3K27me3-specific antibody upon TGFβ treatment in NMuMG 
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cells for 0, 1, 4, 7, 10 and 20 days followed by next generation sequencing (ChIP-Seq) in 
combination with gene expression profiling. Whole genome scanning revealed 970 regions 
corresponding to 301 genes with high variance in H3K27me3 levels during EMT and high 
reproducibility in the biological replicates (Figure 8A). Among the 301 genes, genome-wide 
gene expression analysis identified 46 genes that were transcriptionally up-regulated during 
EMT and lost their H3K27me3 marks and 3 genes that were transcriptionally down-regulated 
during EMT and gained H3K27me3 marks (Figure S6A). We validated the changes in 
H3K27me3 levels at target gene promoters such as Mcam, Pdgfrb, Itga5, Col4a1, and 
St6galnac4 in NMuMG and Py2T cells (Figure 8B, C and Figure S6B) by ChIP followed by 
qPCR for the promoter regions of the genes. The expression of these target genes appeared 
highly dependent on the presence of Ezh1/2 and the H3K27me3 repressive imprint. For 
example, the promoters of the Mcam, Pdgfrb and Itag5 genes were found highly enriched in 
H3K27me3 marks in untreated NMuMG cells. Depletion of Ezh1/2 led to a loss of global 
H3K27me3 levels (Figure S6C) and of H3K27me3 at the promoters of the Mcam, Pdgfrb and 
Itag5 genes (Figure 8D, Figure S6D) with a concomitant increase in their expression (Figure 8E-
F, Figure S6E, F) in NMuMG and Py2T cells. Conversely, the Sgsh gene gained H3K27me3 at 
its promoter during TGFβ-induced EMT with a concomitant repression of its expression and, 
upon Ezh1/2 depletion, the lack of H3K27me3 marks on the Sgsh promoter during TGFβ-
treatment resulted in increased Sgsh gene expression (Figure 8G). In addition, we also 
validated a subset of other H3K27me3-enriched genes that were changing in their expression 
profile upon depletion of Ezh1/2 (Figure 8H). Gene ontology analysis revealed a prominent 
enrichment for gene functions implicated in EMT, malignant tumor progression and metastasis 
(Figure S6G). Furthermore, analysis of the “Minn” database of breast cancer (Minn et al., 2005) 
revealed that the 49 genes signature correlated with reduced bone metastasis-free survival of 
patients in highly malignant breast cancers lacking estrogen receptor expression (ER-) or 
lacking estrogen receptor, progesterone receptor and ErbB2 expression (triple-negative; TN; 
Figure S6H-K). Moreover, in the “Schmidt” database of early stage breast cancer (Schmidt et 
al., 2008), the 49 genes signature correlated with the probability to develop distant metastasis 
(Figure S6L). In line with these findings, transwell migration assays revealed significantly lower 
chemotactic migration of NMuMG and Py2T cells depleted of both Ezh1 and 2 (Ezh1/2) as 
compared to siControl-transfected cells upon treatment with TGFβ (Figure S6M). Together, 
these data indicate that Sox4 regulates Ezh2 gene expression and that Ezh2-mediated 
H3K27me3 marks are critically involved in the transcriptomic reprogramming of cells undergoing 
EMT and that an epigenetic EMT gene signature correlates with breast cancer patient survival. 
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Discussion 
EMT is accompanied by massive changes in cell morphology and behavior, and transcription 
factors play a pivotal role in controlling the various cellular functions during EMT, such as cell 
proliferation, cell survival, cell differentiation, cell migration and cell adhesion. (Hanahan and 
Weinberg, 2011; Kalluri, 2009; Kalluri and Weinberg, 2009; Nieto, 2010; Polyak and Weinberg, 
2009; Thiery and Sleeman, 2006). Here, we have identified the transcription factor Sox4 to be 
up-regulated in its expression and transcriptional activity during EMT in a number of murine and 
human non-transformed mammary gland epithelial cells and breast cancer cells. The 
upregulated expression of Sox4 during TGFβ-induced EMT in NMuMG cells was independent of 
canonical TGFβ signaling, since shRNA-mediated ablation of Smad4 did not substantially affect 
Sox4 expression (data not shown). Moreover, treatment of NMuMG and Py2T cells with 
inhibitors against various signaling pathways revealed that the inhibition of TGFβ receptor and 
Notch signaling and the activation of Wnt signaling interfered with TGFβ-induced Sox4 
expression, while the inhibition of EGF receptor increased Sox4 mRNA levels (data not shown). 
These observations suggest a complex gene regulatory network that drives the increased 
expression of Sox4 during the early phases of TGFβ-induced EMT, perspectives that warrant 
further investigations. 
  We show that Sox4 is not only required for the initiation of EMT, but also for its 
maintenance. Furthermore, Sox4 is crucial for primary tumor growth and metastatic spread of 
Py2T breast cancer and B16-F10 melanoma cells. Finally, we find a significant positive 
correlation between increased Sox4 expression and the metastatic potential of early-stage, 
lymph node-negative breast cancer in patients. These results are consistent with a recent report 
demonstrating that Sox4 is critical for an EMT and tumor growth of human breast cancer cells 
and that Sox4 correlates with poor prognosis in cancer patients (Zhang et al., 2012). 
Despite the recent implications of Sox4 in EMT, its direct transcriptional target genes 
have remained elusive. Here, we show that Sox4 exerts its central function in EMT and tumor 
progression by directly regulating the expression of a number of genes implicated in EMT, cell 
cycle regulation, cell survival and cell migration. Notably, one of the direct targets of Sox4 
transcriptional control is Ezh2, and ablation of Ezh2 function phenocopies the loss of Sox4 
during TGFβ-induced EMT. Moreover, the forced expression of Ezh2 overcomes the failure of 
Sox4-deficient cells to undergo EMT. These results indicate that Ezh2 is a critical downstream 
effector of Sox4 and that Sox4 mediates epigenetic reprogramming via regulating the 
expression of epigenetic modulators during EMT. Consistent with this notion, the concomitant 
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high expression of Sox4 and Ezh2 correlates with poor prognosis in a subset of breast cancer 
patients. These findings are indeed highly relevant, since they unravel a combinatorial action of 
key transcription factors and epigenetic regulators in driving the transcriptional reprogramming 
underlying cell-fate changes during morphogenic processes such as EMT.  
The methyltransferase Ezh2 is the best-studied component of the Polycomb Repressor 
Complex 2 (PRC2). Increased expression or activity of Ezh2 is a marker of advanced and 
metastatic disease in many solid tumors, including prostate and breast cancer (Chase and 
Cross, 2011). Our genome-wide study of Ezh2 associated H3K27me3 mark during EMT 
revealed dynamic changes at a number of genes, of which a subset also shows the 
corresponding changes in transcriptional state. We further show that Ezh1 and Ezh2 together 
determine global as well as promoter-specific H3K27me3 levels. This activity modulates the 
transcriptional state of target genes, including a number of EMT-relevant genes, and it is a 
prerequisite for EMT. Notably, this epigenetic EMT signature significantly correlates with poor 
clinical outcome in patients with highly aggressive and metastatic ER- and triple-negative breast 
cancer. Thus, Polycomb-mediated transcriptional regulation is a critical contributor to the 
maintenance of epithelial differentiation and to the transcriptomic reprogramming during EMT. 
Previously, single gene studies have suggested a role for Ezh2 in EMT regulation. For 
example, the PRC2 complex is recruited to the promoter of the Cdh1 gene for its repression 
(Cao et al., 2008); (Rhodes et al., 2003), and Snail1-mediated repression of Cdh1 during stem 
cell differentiation is PRC2-dependent (Herranz et al., 2008). Notably, Ezh2 forms a co-
repressor complex with HDAC1, HDAC2 and Snail to repress Cdh1 expression and to promote 
nasopharyngeal carcinoma malignancy (Tong et al., 2012). Moreover, the loss of integrin β4 
expression during EMT correlates with a decrease in the activating histone modifications 
H3K9Ac and H3K4me3 and an increase in the repressive histone modification H3K27me3 at its 
promoter (Yang et al., 2009). Thus, previous single genes studies have clearly demonstrated a 
role of PcG-mediated mechanisms in carcinogenesis (Mills, 2010; Sauvageau and Sauvageau, 
2010; Sparmann and van Lohuizen, 2006). By outlining genome-wide targets of the PcG 
machinery during the stepwise progression of EMT and by showing a direct role of Ezh1 and 2 
in the transcriptional regulation of key EMT genes, our study establishes a widespread and 
crucial role for PcG in EMT. We show that the transcription factor Sox4 acts upstream of 
epigenetic reprogramming events during EMT by directly regulating the expression of the 
chromatin regulator Ezh2. Once expressed, Ezh2 and its accompanying chromatin regulators 
need to be recruited to specific target genes during EMT. It is surprising that we have not 
identified the EMT inducers Snail1/2, Twist1/2 and Zeb1/2 as direct targets of PcG-mediated 
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regulation or of Sox4 transcriptional control. Yet, given the critical role of Snail1/2, Twist1/2 and 
Zeb1/2 in regulating EMT and in associating with chromatin regulators, it will be important to 
further delineate the crosstalk of these proteins with the epigenetic machinery and to assess 
whether and how they are targeting epigenetic regulators to specific target genes.  
Sox4 has been previously linked to the etiology of certain cancer types (Penzo-Mendez, 
2010). Interestingly, the closely related family member Sox2 is one of the transcriptional factors 
required to reprogram somatic cells into induced pluripotent stem (iPS) cells (Takahashi and 
Yamanaka, 2006). In glioma-initiating cells, a cross-talk between Sox4 and Sox2 has been 
implicated in maintaining the cells’ tumorigenicity by Sox4 binding to the Sox2 gene enhancer 
region (Ikushima et al., 2009). Together with previous reports that EMT increases the tumor-
initiating (cancer stem cell) potential of cancer cells (Mani et al., 2008; Morel et al., 2008), our 
observation that Sox4 is required for EMT and for metastasis make Sox4 an exciting target for 
further investigations. Our experimental results indicate that Sox4 exerts its critical regulatory 
functions upstream of the Snail, Zeb and Twist family transcriptional inducers of EMT, however, 
without directly affecting their expression. The promoters of the known EMT regulators such as 
Snail1/2, Zeb1/2 or Twist1/2 also did now show any changes in H3K27me3 levels during EMT 
and were not affected following Ezh1/2 depletion (data not shown), suggesting that different 
regulatory pathways may underlie their expression dynamics during EMT. This suggests that 
independent regulatory pathways converge to control genes that drive EMT. These findings 
support our efforts to comprehensively understand the gene regulatory networks that underlie 
an EMT. A recent report demonstrated that Sox9 cooperates with Snail2 to determine mammary 
stem cells and to promote malignant tumor progression (Guo et al., 2012), yet our study did not 
find a requirement of Sox9 for TGFβ-induced EMT in NMuMG and Py2T cells. In contrast, 
another Sox family member, Sox3, was shown to counteract the expression of the EMT-inducer 
Snail1 and, conversely, Snail1 represses Sox3 gene expression during gastrulation and in 
human breast cancer cells (Acloque et al., 2011). We can only speculate that the differences in 
these findings may be based on the functional variety of Sox family members, which are 
classified into subgroups by the differences in their protein moieties outside of the HMG DNA 
binding domains and their varying biological functions (Chew and Gallo, 2009). 
In summary, the data presented here provide critical insights into the regulatory 
networks by which one transcription factor, Sox4, regulates an important cell-fate determination 
event, namely EMT. Notably, the observation that Sox4 regulates a number of EMT-relevant 
genes and Ezh2, and that Ezh2 modifies the expression of a number of genes known to be 
critical for EMT exemplifies a critical interplay between transcriptional and epigenetic control 
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during EMT. Our data suggest that the inhibition of Ezh2 function could be an attractive 
alternative for therapeutic intervention during malignant tumor progression. Indeed, early results 
with the Ezh2 inhibitor 3-deazaneplanocin (DZNep) are encouraging (Crea et al., 2011), and 
first results from clinical trials are impatiently awaited for.  
 
Experimental Procedures 
For more details see Supplemental Information 
 
Cell lines  
A subclone of NMuMG cells (NMuMG/E9; hereafter NMuMG) and MCF7 shControl and MCF7-
shEcad have been previously described (Lehembre et al., 2008; Maeda et al., 2005). B16-F10 
melanoma cells, EpRas, and MCF10A cells were commercially available. Py2T cells were 
derived from a breast tumor of MMTV-PyMT transgenic mice (Waldmeier et al., 2012).  
 
Chromatin immunoprecipitation (ChIP)  
ChIP experiments were performed as previously described (Weber et al, 2007). In brief, 
crosslinked chromatin was sonicated to achieve an average fragment size of 500bp. Starting 
with 100µg of chromatin and 5µg of anti-HA antibody or anti-H3K27me3 antibody. 1µl of ChIP 
material and 1µl of input material were used for quantitative real-time PCR using specific 
primers covering the motif of Sox4 in the promoter of target genes or covering the 1000bp 
promoter region from the transcription start site. Primers covering an intergenic region were 
used as a control. The efficiencies of PCR amplification were normalized to the PCR product of 
the intergenic region. Primer sequences are listed in Supplemental Information. 
 
Next Generation Sequencing Analysis  
The reads were mapped to the mouse genome assembly NCBI37/mm9 using the bowtie 
algorithm (Langmead et al., 2009) allowing up to 2 mismatches within the 36bp-long sequence. 
Reads which mapped to more than 100 loci were discarded from the subsequent analysis. In 
total, 24 to 34 million reads were mapped to the genome in the first replicate and from 95 to 106 
million reads in the second replicate. The mean DNA fragment size was estimated from the 
mapping profile on both chromosome strands and the reads were shifted by the half of the size 
towards the middle of the fragment. This data was exported to wiggle tracks for manual 
inspection in the UCSC genome browser and served as an input for the enrichment analysis. 
The genome was tiled with 2kb windows overlapping by 1kb and each window was summarized 
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by the numbers of reads in both replicates at every stage and the number of reads in the input 
DNA. The H3K27me3-enrichment was calculated assuming binomial statistics of the read 
counts 𝑧 = !!!!!!!!!!!!∙ !!!!!!!! !!!∙ !!!!!!!!!! , where 𝑓! = !!!! is the frequency in the 2kb window calculated from 
the number of reads in the window 𝑛! and the total number of reads 𝑁! in the sample i and S=12 
is the number of samples in both replicates. The background frequencies 𝑓! are calculated 
analogously. Neighboring windows with 𝑧 ≥ 5 and 𝑛! ≤ 50 were merged and intersected with 
RefSeq loci extended by 1kb upstream and 1kb downstream. From the list of 96’224 such 
enriched regions a subset was selected by requiring dynamic (mean variance log-frequencies > 
0.2) and consistent (Pearson correlation coefficient of log-frequencies > 0.5) methylation 
changes. The resulting 970 regions lie within 1 kilobase of the loci of 301 genes. 
 
Animal experimentation 
All studies involving mice have been approved by the Swiss Federal Veterinary Office (SFVO) 
and the regulations of the Cantonal Veterinary Office of Basel Stadt (licences 1878, 1907, 
1908). 
 
Statistical analysis 
Statistical analysis and graphs were generated using the GraphPad Prism software (GraphPad 
Software Inc, San Diego, CA). All statistical analysis was done by unpaired/paired, two-sided t-
test. 
 
Accesssion numbers 
Gene expression data of Sox4 knockdown cells in the presence and absence of TGFβ in 
NMuMG cells and  ChIP-seq data of H3K27me3 imprints during TGFβ-induced EMT in NMuMG 
cells are deposited at Gene Expression Omnibus (GSE44050 and GSE45579, respectively).        
 
Supplemental Information 
Supplemental Information including 6 figures, 2 tables, and extended experimental procedures 
can be found online at XXXXX. 
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Figure Legends 
 
Figure 1. Sox4 is required for EMT.  
(A) Sox4 mRNA levels were determined by quantitative RT-PCR in NMuMG cells transfected 
with either control siRNA (siControl) or with siRNA against Sox4 (siSox4) in the absence or 
presence of TGFβ for 2 days. Fold changes are shown in comparison to cells transfected with 
control siRNA in the absence of TGFβ.  
(B) NMuMG cells transfected with either siControl or with siSox4 were treated with TGFβ for the 
days indicated and their morphology was evaluated by phase contrast microscopy. Size bar, 
100µm. 
(C) Immunoflorescence microscopy analysis of changes in the localization and expression 
levels of marker proteins during EMT. NMuMG cells transfected with either siControl or with 
siSox4 were left untreated or treated with TGFβ for 2 days and stained with antibodies against 
the epithelial markers E-cadherin and ZO-1, against the mesenchymal marker N-cadherin, 
against paxillin to detect focal adhesion plaques, and with phalloidin to visualize the actin 
cytoskeleton. Size bar, 50µm. 
(D) Expression of E-cadherin, N-cadherin and fibronectin was determined by immunoblotting 
during TGFβ-induced EMT in NMuMG cells transfected either with siSox4 or siControl. 
Immunoblotting for actin was used as a loading control.   
(E) Morphology of long-term TGFβ-treated NMuMG (NMuMG-LT) cells transfected with either 
siControl or siSox4 as evaluated by phase contrast microscopy. Size bar, 100µm. 
Statistical values were calculated using a paired, two-tailed t-test. ** = p ≤ 0.01; *** = p ≤ 0.001; 
error bars = ±SD. See also Figure S1. 
 
Figure 2. Sox4 is required for cell survival and cell migration during TGFβ-induced EMT.  
(A, B) siRNA or shRNA-mediated ablation of Sox4 expression (siSox4 and shSox4, 
respectively) during TGFβ treatment of NMuMG (A) and Py2T (B) cells results in a significant 
decrease in cell numbers as compared to cells transfected with control siRNA or shRNA 
(siControl and shControl, respectively). 
(C, D) NMuMG cells (C) or Py2T cells (D) transfected with either siControl and shControl or with 
siSox4 and shSox4 were treated with TGFβ for the days indicated (d0 to d4). Cells were stained 
with propidium iodide (PI), and the percentages of cells in G0/G1 and S-G2/M phases of the cell 
cycle were determined by flow cytometry.  
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(E) NMuMG cells transfected with either siControl or with siSox4 were treated with TGFβ for the 
days indicated, and the rates of apoptosis were determined by Annexin-V staining and flow 
cytometry. 
(F) shSox4-expressing and shControl-expressing Py2T murine breast cancer cells were treated 
for 15 days with TGFβ and cell migration was determined in a modified Boyden chamber 
migration assay 20 hours after seeding and using 20% FBS as a chemoattractant.  
Statistical values were calculated using an unpaired, two-tailed t-test. * = p  ≤ 0.05; ** = p ≤ 
0.01; *** = p ≤ 0.001; error bars = ±SD. 
 
Figure 3. Ectopic expression of Sox4 promotes EMT and cell migration.  
(A) NMuMG cells were transiently transfected with pcDNA3-HA and pcDNA3-HA-Sox4 
constructs and cellular morphology was evaluated. Note the formation of filopodia and cell 
dispersal upon Sox4 expression (HA-Sox4) as compared to empty vector control (Empty). Size 
bar, 100µm. 
(B) The expression of E-cadherin (Ecad), N-cadherin (Ncad), fibronectin (Fn1), Ezh2 and Sox4 
was determined by quantitative RT-PCR in NMuMG cells transiently transfected with HA-Sox4 
or with empty vector (Empty) in the absence of TGFβ. Fold changes are shown in comparison to 
cells transfected with empty vector.  
(C) The expression of E-cadherin, N-cadherin, fibronectin, Ezh2 and HA-tagged Sox4 was 
determined by immunoblotting of NMuMG cells transiently transfected with empty vector or with 
HA-Sox4. Actin was used as loading control. 
(D) The localization of E-cadherin was determined by immunofluorescence staining in NMuMG 
cells transiently transfected with empty vector control or with HA-Sox4. The cells marked with an 
arrow express Sox4 (HA) and have lost E-cadherin at their cell membranes. Size bar, 50µm. 
(E) Cell scattering and mesenchymal morphology is observed even in the absence of TGFβ in 
Py2T cell clones stably expressing HA-Sox4 (Clone 3 and 5) as compared to empty vector-
transfected control cells (Empty). Size bar, 100µm. 
(F) The expression of E-cadherin (Ecad), N-cadherin (Ncad), fibronectin (Fn1), and Sox4 was 
determined by quantitative RT-PCR in Py2T cell clones either stably transfected with HA-Sox4 
(Clone 3 and 5) or with control vector (Empty) in the absence of TGFβ. Fold changes are shown 
in comparison to cells transfected with the control vector.  
(G) Immunoblotting analysis of E-cadherin, N-cadherin, fibronectin, Ezh2 and HA-Sox4 (HA) 
during TGFβ-induced EMT in Py2T cell clones either stably transfected with HA-Sox4 (Clone 3 
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and 5) or with empty control vector (Empty) in the absence of TGFβ. Vinculin was used as 
loading control.  
(H) Cell migration of Py2T cell clones stably transfected with HA-Sox4 (Clone 3 and 5) or 
transfected with control vector (Empty) was analyzed in a trans-well migration assay in the 
absence of TGFβ after 20 hours  of cell seeding with 20% FBS as a chemoattractant. 
Statistical values were calculated using an unpaired, two-tailed t-test. * = p ≤ 0.05; ** = p ≤ 0.01; 
*** = p ≤ 0.001; error bars = ±SD. 
 
Figure 4. Sox4 is critical for breast carcinogenesis and metastasis.  
(A) Correlation of the levels of Sox4 expression and prognosis in the “Schmidt” array data set of 
lymph node-negative breast cancers (Schmidt et al., 2008). Shown is a Kaplan-Meier survival 
curve for patient samples classified for having high Sox4 expression and low Sox4 expression 
to assess metastasis-free survival.  
(B) shSox4-expressing and shControl-expressing Py2T murine breast cancer cells were 
injected into the mammary fat pad of nude mice and the resulting tumors were analyzed by 
immunohistochemistry for Sox4 expression. High magnification as indicated by boxed areas 
shows that shControl-transfected cells localize Sox4 primarily in the nucleus and exhibit spindle-
like cell morphology, while shSox4-expressing cells lack significant Sox4 expression and exhibit 
a more differentiated morphology.  
(C) shSox4-expressing and shControl-expressing Py2T cells were injected into the mammary 
fat pad of nude mice and tumor growth in individual mice was measured over time (top panel). 
Tumor weight was assessed after sacrificing the tumor-bearing mice 23 days after injection 
(bottom panel).  
(D) Metastatic spread of firefly luciferase-expressing Py2T cells from the primary tumors 
analyzed in panel C was determined by measuring luciferase activity in extracts of lymph nodes 
(LN), lungs and livers of transplanted mice. Luciferase activity levels in the various organs were 
divided by the primary tumor weights within the same mice to establish the metastatic index. 
Numbers indicate the fold-differences between Sox4-expressing (shControl) and Sox4-depleted 
(shSox4) Py2T cells. Error bars, ±SE. 
(E) Primary tumor growth of shControl and shSox4 Py2T cells upon subcutaneous injection into 
nude mice (left panel). Tumor weight was assessed 27 days after implantation (right panel).  
Statistical values were calculated using an unpaired, two-tailed t-test. * = p  ≤ 0.05; ** = p ≤ 
0.01; *** = p ≤ 0.001; error bars = ±SEM. See also Figure S2. 
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Figure 5. Sox4 directly regulates Ezh2 gene expression.  
(A-B) NMuMG cells (A) and Py2T cells (B) were transiently transfected with a construct 
encoding HA-Sox4 or empty vector and used for Chromatin Immunoprecipitation (ChIP) in the 
absence and presence of TGFβ for 2 days using HA-specific antibodies. Precipitated DNA 
fragments corresponding to Ezh2 promoter sequences were detected by quantitative PCR to 
assess Sox4 occupancy at this region. Fold changes are shown in comparison to a PCR 
reaction with primers specific for an intergenic region.  
(C) Levels of Ezh2 mRNA were determined by quantitative RT-PCR in NMuMG cells or Py2T 
cells transfected with control siRNA (siControl) or siRNA against Sox4 (siSox4) in the presence 
of TGFβ for 2 days. Fold changes are shown in comparison to siControl-transfected cells (top 
panels). Global H3K27me3 levels were determined by immunoblotting in NMuMG cells or Py2T 
cells transfected with siControl or siSox4 and treated with TGFβ for 2 days. Total histone H3 
was used as loading control (bottom panels). 
(D) Sox4 regulates Ezh2 promoter activity. NMuMG cells were transiently transfected with 
siControl or siSox4 and with a pGL3 luciferase reporter plasmid containing a 1.9kb fragment of 
the Ezh2 promoter controlling the expression of firefly luciferase and then treated with or without 
TGFβ for 2 days. Firefly luciferase activity was normalized to co-transfected renilla luciferase 
activity (relative luminescence).  
(E, F) Sox4 and Ezh2 expression levels were determined by quantitative RT-PCR after transient 
transfection of NMuMG (E) and Py2T cells (F) with siControl or siSox4 during the first hours of 
TGFβ treatment (0, 2, 4 and 8 hours). 
Statistical values were calculated using a paired, two-tailed t-test. * = p ≤ 0.05; ** = p ≤ 0.01; *** 
= p ≤ 0.001; error bars = ±SD. See also Figure S3 and Tables S1 and S2. 
 
Figure 6. Depletion of Ezh2 phenocopies the ablation of Sox4 during TGFβ-induced EMT. 
(A) NMuMG cells transfected with either control siRNA (siControl) or with siRNAs against Ezh2 
or Ezh1 and Ezh2 together (siEzh1/2) were treated with TGFβ for the days indicated and their 
morphology was evaluated by phase contrast microscopy. Size bar, 100µm. 
(B) Expression of E-cadherin, N-cadherin, ZO-1 and Ezh2 was determined by immunoblotting 
analysis during TGFβ-induced EMT in NMuMG cells transfected either with siEzh2 or siControl. 
Immunoblotting for actin was used as a loading control.   
(C) Immunoflorescence microscopy analysis of NMuMG cells transfected with either siControl or 
with siEzh2 or siEzh1/2. Cells were treated with TGFβ for 7 days and stained with antibodies 
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against E-cadherin, ZO-1, and fibronectin, and with phalloidin to visualize the actin cytoskeleton. 
Size bar, 50µm. 
(D) NMuMG cells transfected with either siControl or with siEzh2 were treated with TGFβ for the 
days indicated, and the rates of apoptosis were determined by Annexin-V staining and flow 
cytometry. 
(E) siControl and siEzh2-transfected NMuMG cells were treated with TGFβ for the days 
indicated. Cells were stained with propidium iodide (PI), and the percentages of cells in G0/G1 
and S-G2/M phases of the cell cycle were determined by flow cytometry.  
(F) siRNA-mediated ablation of Ezh2 expression during TGFβ treatment of NMuMG cells results 
in a significant decrease in cell numbers as compared to cells transfected with control siRNA.  
(G) Kaplan-Meier survival curve for patient samples of the “Schmidt” array data set of lymph 
node-negative breast cancers (Schmidt et al., 2008) classified for having concomitant low Sox4 
and Ezh2 expression and high Sox4 and Ezh2 expression to assess metastasis free survival.  
Statistical values were calculated using an unpaired, two-tailed t-test. * = p  ≤ 0.05; ** = p ≤ 
0.01; *** = p ≤ 0.001; error bars = ±SD. See also Figure S4 
 
Figure 7. Forced expression of Ezh2 overcomes the lack of Sox4 and restores TGFβ-induced 
EMT.  
(A) While ablation of Sox4 expression (siSox4) repressed the TGFβ-induced mesenchymal 
morphology of NMuMG cells observed in siControl-transfected cells, transient expression of 
Ezh2 in Sox4-ablated cells (siSox4 + Ezh2) restored EMT and mesenchymal cell morphology. 
Cells were treated with TGFβ for the indicated times. Size bar, 100µm. 
(B, C) mRNA expression levels of E-cadherin (C) and fibronectin (D) were determined after 
Ezh2 overexpression (+Ezh2) in control (shControl) and Sox4-ablated (shSox4) Py2T cells. 
Statistical values were calculated using an unpaired, two-tailed t-test. * = p  ≤ 0.05; ** = p ≤ 
0.01; *** = p ≤ 0.001. See also Figure S5. 
 
Figure 8. TGFβ-induced EMT accompanies genome-wide reprogramming of the Polycomb-
associated mark H3K27me3. 
(A) TGFβ-induced EMT accompanies genome-wide reprogramming of the Polycomb-associated 
mark H3K27me3. Genome-wide H3K27me3 enrichment above background was calculated for 
2kb-wide windows overlapping by 1kb. To extract those H3K27me3-regions that are most 
relevant for EMT dynamics, for each region both the variance in H3K27me3 levels during the 
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progressive stages of EMT (horizontal axis) and the reproducibility of the H3K27me3 dynamics 
across biological replicates (vertical) axis was calculated and 970 genes with high variance and 
high reproducibility were selected. Comparison of these regions with RefSeq transcripts show 
that they fall within 1kb upstream and downstream of 301 distinct target genes. 
(B, C) ChIP was performed using an H3K27me3-specific antibody in NMuMG cells and the 
enrichment of H3K27me3 was determined by quantitative PCR at the promoters of the Mcam, 
Pdgfrb and Sgsh genes during TGFβ-induced EMT (B) and at the promoters of the Itga5, 
Col1a1 and St6galnac4 genes in the absence of TGFβ (C). Average enrichments from 
independent assays are plotted on the y axis as the ratio of precipitated DNA relative to the total 
input DNA and further normalized to the Gapdh house-keeping gene promoter.  
(D) ChIP was performed using an H3K27me3-specific antibody in NMuMG cells transiently 
transfected with control siRNA (siControl) or siRNA against Ezh1/2 (siEzh1/2), and quantitative 
PCR was performed using promoter-specific primers as indicated to determine enrichment of 
H3K27me3 at the Mcam, Pdgfrb, and Itga5 promoters and normalized to the Gapdh house-
keeping gene promoter. 
(E - G) NMuMG cells transiently transfected with control siRNA (siControl) or siRNA against 
Ezh1/2 (siEzh1/2) were analyzed by quantitative RT-PCR analysis for the mRNA expression 
levels of Mcam (E) and Pdgfrb (F) which already carry high H3K27me3 marks in untreated 
NMuMG cells and lose this mark during EMT, and of Sgsh (G) which gains this mark upon 
TGFβ treatment for 1, 4, 7 and 10 days. 
(H) Validation of selected genes enriched in H3K27me3 marks and their transcriptional de-
repression after Ezh1/2 ablation in NMuMG cells in the absence of TGFβ. 
Statistical values were calculated using a paired, two-tailed t-test. * = p ≤ 0.05; ** = p 
≤ 0.01; *** = p ≤ 0.001; error bars = ±SD. See also Figure S6 and Tables S1 and S2. 








